anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
BACKGROUND: The extent to which the relationships between clinical risk factors and coronary artery disease (CAD) are altered by CAD polygenic risk score (PRS) is not well understood. Here, we determine whether the interactions between clinical risk factors and CAD PRS further explain risk for incident CAD.
METHODS: Participants were of European ancestry from the UK Biobank without prevalent CAD. An externally trained genome-wide CAD PRS was generated and then applied. Clinical risk factors were ascertained at baseline. Cox proportional hazards models were fitted to examine the incident CAD effects of CAD PRS, risk factors, and their interactions. Next, the PRS and risk factors were stratified to investigate the attributable risk of clinical risk factors.
FINDINGS: A total of 357,144 individuals of European ancestry without prevalent CAD were included. During a median of 11.1 years of follow-up (interquartile range 10.4-14.1 years), CAD PRS was associated with 1.35-fold (95% confidence interval [CI] 1.332-1.368) risk per SD for incident CAD. The prognostic relevance of the following risk factors was relatively diminished for those with high CAD PRS on a continuous scale: type 2 diabetes (hazard ratio [HR]interaction 0.91, 95% CIinteraction 0.88-0.94), increased body mass index (HRinteraction 0.97, 95% CIinteraction 0.96-0.98), and increased C-reactive protein (HRinteraction 0.98, 95% CIinteraction 0.96-0.99). However, a high CAD PRS yielded joint risk increases with low-density lipoprotein cholesterol (HRinteraction 1.05, 95% CIinteraction 1.04-1.06) and total cholesterol (HRinteraction 1.05, 95% CIinteraction 1.03-1.06).
CONCLUSION: The CAD PRS is associated with incident CAD, and its application improves the prognostic relevance of several clinical risk factors.
FUNDING: P.N. (R01HL127564, R01HL151152, and U01HG011719) is supported by the National Institutes of Health.
The invention relates to a folium artemisiae argyi powder which is a medicine for treating traumatic injuries, arthralgia and myalgia and numbness of limbs. Specifically, the folium artemisiae argyi powder is a Chinese patent medicine prepared by taking Chinese herbal medicines as raw materials, and the Chinese patent medicine is used to treat adhesion, rigidity, scleroma and joint function activity limitation caused by fracture and soft tissue damage. The invention also relates to a preparation method for the medicine. The medicine employs folium artemisiae argyi, pericarpium zanthoxyli, trberculate speranskia herb, flos carthami, radix saposhnikoviae, herba ephedrae, radix clematidis, herba schizonepetae, ramulus cinnamomi, radix angelicae pubescentis, bark of oriental variegated coralbean and radix angelicae dahuricae as bulk drugs, and an externally-applied powder is prepared by performing screening, drying and crushing on the raw materials. The provided formula is definite in therapeutic effect, and is an ideal medicine capable of rapidly adhesion, rigidity, scleroma and joint function activity limitation caused by fracture and soft tissue damage. The medicine is simple in preparation method, and easy for processing and large-scale production.
Dental fillings, crowns and prostheses are made from a mixture of an epoxy resin and a hardening agent, the latter being either a stable complex of a Friedel-Craft's catalyst or boron trifluoride with an organic compound.  Suitable catalysts are stannic chloride, antimony pentachloride, zinc chloride and boron tri-fluoride and, if desired, these may be dissolved in a suitable solvent, preferably one which reacts with the resin to take part in the hardening action, such as alcohol.  Polyglycidal ethers or esters are suitable resins but mixtures may be used.  For convenience in use the catalyst may be stored as a liquid or as a paste, in the latter case, by being mixed with finely dispersed silica.ALSO:Dental fillings, crowns and prostheses are made from a mixture of an epoxy resin and a hardening agent, the latter being either a stable complex of a Friedel-Craft's catalyst or boron trifluoride with an organic compound.  Suitable catalysts are stannic chloride, antimony pentachloride, zinc chloride and boron trifluoride and, if desired, these may be dissolved in a suitable solvent, preferably one which reacts with the resin to take part in the hardening action, such as alcohol.  Polyglycidal ethers or esters are suitable resins but mixtures may be used.  For convenience in use the catalyst may be stored as a liquid or as a paste, by being mixed with finely-dispersed silica.
ABSTRACT OF THE DISCLOSURE Methods and compositions are described for liquid or gel forms of a lipid excipient to be used in pharmaceutical or cosmetic preparations. The lipid excipient comprises a phospholipid such as a lysophospholipid, for example, mono-oleoyl-phos-phatidylethanolamine ("MOPE"). Relatively low concentrations of the lipid can be employed in forming the gel, e.g., about 1-2%. The invention discloses the use of a lipid delivery system at a relatively low lipid concentration as a non-toxic, non-irritating carrier or excipient alone or in combination with other agents, for both drugs and cosmetics. For example, the lipid excipient in sprayable or dropable form has special utility in the non-irritating delivery of peptides (e.g., calcitonin and insulin) to the nasal mucosa, due to the ability of the excipient to enhance absorption across nasal membranes. As a cosmetic, it can be used alone or in combination with biologically active agents.
This group will participate in a weekly exercise regimen and actively log the physical activity in a diary. They will complete the daily hot flash diary, MENQOL scale and calorimeter. All subjects will complete questionnaire (MENQOL Scale,) before the start of the study, at the sixth week of the study and after the completion of the twelfth week. A 2-week baseline assessment of hot flashes using the hot flash diary and fitbit flex will be followed by 12 weeks of assessment during the exercise intervention.
Materials and methods are provided for treating influenza B infections in humans. Anti-human influenza virus monoclonal antibodies and antigen-binding fragments thereof having a neutralization activity against a human influenza B virus are provided. Methods for producing anti-human influenza B virus monoclonal antibodies are also provided. The antibodies and antigen-binding fragments thereof can be effective against a wide range of influenza B viral strains. Methods of inhibiting or treating a human influenza B infection are provided. The anti-influenza B therapeutics can also be used to manufacture medicaments effective against influenza B infections, to detect human influenza B in a human subject, for use in pharmaceutical compositions, and for use in kits for at least one of the prevention, the treatment, and the detection of human influenza B in a human subject.
The present application relates to an antigen binding protein comprising a VH and a VL, wherein the VH comprises HCDR1, HCDR2 and HCDR3, the HCDR1 comprises the amino acid sequence shown in SEQ ID No. 10, the HCDR2 comprises the amino acid sequence shown in SEQ ID No. 12, the HCDR3 comprises the amino acid sequence shown in SEQ ID No. 14; wherein the VL comprises LCDR1, LCDR2 and LCDR3, the LCDR1 comprises the amino acid sequence shown in SEQ ID NO. 2, the LCDR2 comprises the amino acid sequence shown in SEQ ID NO. 4, and the LCDR3 comprises the amino acid sequence shown in SEQ ID NO. 6. The application also relates to pharmaceutical compositions comprising said pro-binding proteins and their use for the treatment of cancer.
<P>PROBLEM TO BE SOLVED: To provide a permanent wave lotion which is harmless for human bodies, is used for waving/curling the hair, and can arrange the tips of the curled hair for a long time without deteriorating the natural environment.  <P>SOLUTION: The first liquid for the permanent wave lotion for waving/curling the hair comprises 25 to 50 wt. % of boiled water, 25 to 50 wt. % of a mixture comprising 1 liter of water and 10 to 200g of sodium bicarbonate, and 5 to 25 % of L-cysteine. The boiled water is prepared by passing water (created water) through an ion exchange resin, and then through a mixture of tourmaline with at least one of aluminum, stainless steel and silver or a rock mixture comprising at least one of obsidian, perlite and pitch stone, and then further through the remaining mixture, and then boiling the treated water to give a pH value of 8.5 to 10.0. The first liquid for the permanent wave lotion cuts the S-S bonds of the hair to facilitate the curling of the hair. The second liquid for the permanent wave lotion comprises 15 to 35 wt. % of the created water, 15 to 35 wt. % of citric acid or Japanese prune vinegar, and 30 to 70 wt. % of sodium bicarbonate. The second liquid for the permanent wave lotion makes it possible to hold the curled state of the hair for a long time.  <P>COPYRIGHT: (C)2004,JPO
The study will be conducted in Mexico City under the sponsorship of Zélé® and in collaboration with the VIME Weight Loss and Wellness Center of Mexico. During the year 2021 and with follow-up for 24 months. An open call will be made through different media including social networks for the recruitment of patients who meet the inclusion criteria and must present themselves for a clinical evaluation in which pathological history, clinical status, heart rate, blood pressure, oxygenation and temperature will be recorded. Nutritional assessment, and a Complete Blood Count, a biochemical profile. Patients who meet all the inclusion criteria will be selected and will have an interview with the principal investigator in which they will sign their letter of commitment and informed consent, then they will be subjected to the randomization process with a 2:1 allocation for treatment and controls, respectively. Subsequently, they will be submitted to the two nutritional treatments and will be clinically evaluated every week and will receive nutritional, psycho emotional and physical activity counseling. At each visit, adverse effects, changes in clinical status will be recorded and the presence of ketone bodies in capillary blood will be determined. Subsequently, only clinical and nutritional follow-up will be given along with psycho-emotional support and physical activity advice every 3 months up to 12 months and every 6 months up to 24 months.
PROBLEM TO BE SOLVED: To obtain a pigment which is smooth and excellent in adhesion to skin and in color-spreading capability by coating the surface of a pigment with a hydrophobizing agent and a homogeneous melt mixture comprising a liq. satd. fatty acid ester and a purified ester gum consisting mainly of abietic acid triglyceride. SOLUTION: 33-66 wt.% purified ester gum consisting mainly of abietic acid triglyceride is homogeneously mixed with a liq. satd. fatty acid ester to give a homogeneous melt mixture. The surface of a pigment or a body pigment is coated with, based on the pigment or body pigment, 0.5-20 wt.%, pref, 2-10 wt.%, above-prepd. melt mixture and 0.5-20 wt.%, pref. 1-7 wt.%, hydrophobizing agent or 0.1-20 wt.%, pref. 2-10 wt.%, hydrolipophobizig agent. Thus is obtd. a cosmetic which is free from darkening of color due to sweat or sebum, does not cause makeup to come off, and does not irritate skin.
This prospective, randomized, triple-armed trial compared the effectiveness of three different anesthetic approaches for intravitreal injections. Were included 92 consecutive patients scheduled to receive intravitreal injection of bevacizumab (Avastin, Genentech, Inc.) in one eye, from June 2014 to September 2014, evaluated at at a single center - Retina Clinic, Osasco, São Paulo, Brazil. The same ophthalmologist (CGA) administered both, anesthetic and therapeutic, injections. A masked nurse collected patient assessment responses and a masked statistician performed statistical analyses. The research followed the tenets of the Declaration of Helsinki and was approved by the Committee of Ethics in Research. All participants gave written informed consent prior to their participation.

Patients were randomized to 1 of 3 groups before injection: proparacaine 0.5% drops (Anestalcon®, Alcon Lab. do Brasil Ltda, São Paulo, Brazil), (Group Drops), proparacaine plus subconjunctival lidocaine 1% (Xylestesin®, Cristália, São Paulo, Brazil) (Group SC), or 2% lidocaine gel (Xylestesin®, Cristália, São Paulo, Brazil) (Group Gel).

A standardized method was used to prepare the injection site and disinfect the skin using povidone iodine 10%. Patients from groups Drops and SC received a drop of proparacaine 0.5% before receiving a drop of povidone iodine 5%. For the patients from Group Gel, the gel was placed on the eye before receiving the drop of povidone iodine 5%. Patients from Group Drops received a second drop of proparacaine 0.5%, 5 minutes after the drop of povidone iodine 5%. For the patients from Group SC, a subconjunctival bleb of anesthesia was created by injecting 0.4 ml of lidocaine 1% into the subconjunctival space, posteriorly to the superotemporal limbus with a 30-gauge, 1/2-inch needle attached to a 1-ml syringe. After 5 minutes of the drop of povidone iodine 5%, sterile field and a lid speculum were placed. The injection site was measured with calipers to be 3.5 mm or 4.0 mm posterior to the superotemporal limbus, for pseudophakic and phakic eyes, respectively. A 30-gauge 1/2-inch needle was used to inject 0.05 ml of bevacizumab (Avastin, Genentech, Inc.). After the injection, mild pressure was applied with a swabstick over the injection site to reduce vitreous reflux and subconjunctival hemorrhage another a drop of povidone iodine 5% was applied.

Immediately following the injection, a nurse, who was masked to the treatment, explained the 100-mm visual analog scale (VAS) for pain (Figure 1) and questioned the patients' level of pain perceived during the injection. This assessment was repeated 10 minutes, 1 hour, 6 hours and 24 hours later, without visualization of their prior responses. Patients were also asked to grade their overall experience with the injection procedure as Excellent (5), Very good (4), Fair (3), Poor (2) or Awful (1). The physician evaluated the patients' eye movement during intravitreal injection into three levels: none or minimal (0), not compromising the injection (1), compromising the injection (2). Complications that occurred during or after the procedures were also recorded.
BACKGROUND: Lymphoedema is a globally neglected health care problem and a common complication following breast cancer treatment. Lymphoedema is a well-known predisposing factor for cellulitis, but few have investigated the risk factors for cellulitis in this patient cohort on an international level. The aim of this study was to identify the frequency of cellulitis in patients with lymphoedema of the arm, including potential risk factors for cellulitis.
METHODS: An international, multi-centre, cross-sectional study including patients with clinically assessed arm lymphoedema. The primary outcome was the incidence of cellulitis located to the arm with lymphoedema within the last 12 months, and its potential associated risk factors. The secondary outcome was life-time prevalence of cellulitis. Adults with clinically-assessed arm lymphoedema/chronic oedema (all causes) and able to give informed consent were included. End-of-life-patients or those judged as not in the patient's best interest were excluded. Both univariable and multivariable analysis were performed.
RESULTS: A total of 2160 patients were included from Australia, Denmark, France, Ireland, Italy, Japan, Turkey and United Kingdom. Secondary lymphoedema was present in 98% of the patients; 95% of these were judged as related to cancer or its treatment. The lifetime prevalence of cellulitis was 22% and 1-year incidence 11%. Following multivariable analysis, factors associated with recent cellulitis were longer swelling duration and having poorly controlled lymphoedema. Compared to having lymphoedema less than 1 year, the risk increased with duration: 1-2 years (OR 2.15), 2-5 years (OR 2.86), 5-10 years (OR 3.15). Patients with well-controlled lymphoedema had a 46% lower risk of cellulitis (OR 0.54, 95% CI 0.39-0.73, p < 0.001). More advanced stages of lymphoedema were associated with cellulitis even after adjustment for swelling duration and control of swelling by logistic regression (stage II OR 5.44, stage III OR 9.13, p = 0.002), demonstrated in a subgroup analysis.
CONCLUSION: Patients with advanced arm lymphoedema are at particular risk of developing cellulitis. Prevention of lymphoedema progression is crucial. The results lend towards a positive effect of having well-treated lymphoedema on the frequency of cellulitis.
Chronic Obstructive Pulmonary Disorder manifested as breathlessness, respiratory difficulties and persistent cough is one of the biggest causes of mortality around the world. 2.1% of Pakistani population has COPD. Proprioceptive neuromuscular facilitation is used as management technique in which muscle stretching promotes chest wall mobility and restores regular breathing rhythm. In previous studies, PNF technique combined with aerobic exercises has been utilized to improve Pulmonary functions in COPD patients. But the sample size of these studies was small and participants were ventilated patients, hence not targeting the diaphragm. Our study shall evaluate the impact of PNF technique combined with aerobic training on the Pulmonary function of COPD patients in the clinical setting.
The purified hematopoietic stem cells (HSC) transplantation-related complications includes graft failure and graft rejection. Previous studies have demonstrated that the facilitating cells (CD8+/TCR-) enhance engraftment of purified HSC in allogeneic recipients without causing graft-versus-host disease (GVHD). It is hypothesized that a specific MHC molecule strongly influences engraftment of HSC mediated by facilitating cells. The present invention identifies which MHC loci are essential for curable engraftment of purified allogeneic HSC. Inbred mouse strain combinations congenic for all except specific MHC class I or II loci were utilized as donors and recipients. Recipients were reconstituted with 5000 HSX of donor mice following 950 cGy of total body irradiation. Matching at class I D is not essential for HSC engraftment. If the donor and recipient are disparate at the class I K and class II-A locus, impaired engraftment of HSC occurs. Matching at class I K appears to be the most critical, as reflected in failure of long-term stable engraftment of HSC on allogeneic recipients without causing GVHD. The present invention demonstrates that MHC class I K molecule is essential for maintaining the self-renewal capability of purified HSC. Moreover, interaction between the HSC and FC via the MHC class I K molecule provides a regulatory function to promote engraftment and survival of allogeneic HSC.
PURPOSE:An ameliorant, containing an iridoide or a glycoside thereof, useful for preventing and improving psychogenic sexual dysfunction, amnesia or senile dementia, etc., and effective for disorder due to stress. CONSTITUTION:An ameliorant, containing an iridoide, a glycoside or salt thereof as an active constituent, and effective for disorder due to stress. The iridoide is a generic name of monoterpenes having the formula as a basic skeleton, and widely distributed in higher plants. The laxative, diuretic or chloagogic action, etc. is well known as the physiological activity thereof but newly found to have a preventing and remedial effect on disorder due to stress. Geniposidic acid, geniposide, gardenoside, etc. may be cited as the suitable iridoide. The ameliorant can be used for preventing and improving various disorders due to strong stress, particularly psychogenic sexual dysfunction, amnesia or senile dementia, etc. and has low toxicity.
Patients undergoing continued treatment with valsartan after improvement of LVEF \>40% with \> 3 months of sacubitril/valsartan treatment. Dose and titration schedule will be individualized by discretion of the attending physician.
In spite of the vaccine development and its importance, the SARS-CoV-2 pandemic is still impacting the world. It is known that the COVID-19 severity is related to the cytokine storm phenomenon, being inflammation a common disease feature. The nicotinic cholinergic system has been widely associated with COVID-19 since it plays a protective role in inflammation via nicotinic receptor alpha 7 (nAchRalpha7). In addition, SARS-CoV-2 spike protein (Spro) subunits can interact with nAchRalpha7. Moreover, Spro causes toll-like receptor (TLR) activation, leading to pro- and anti-inflammatory pathways. The increase and maturation of the IL-1 receptor-associated kinase (IRAK) family are mediated by activation of membrane receptors, such as TLRs. IRAK-M, a member of this family, is responsible for negatively regulating the activity of other active IRAKs. In addition, IRAK-M can regulate microglia phenotype by specific protein expression. Furthermore, there exists an antagonist influence of SARS-CoV-2 Spro and the cholinergic system action on the IRAK-M pathway and microglia phenotype. We discuss the overexpression and suppression of IRAK-M in inflammatory cell response to inflammation in SARS-CoV-2 infection when the cholinergic system is constantly activated via nAchRalpha7.
Introduction: Temporomandibular joint disc displacement is a disorder in which the articular disc is anteriorly displaced from its correct position in relation to the mandibular condyle and mandibular fossa. Traditionally, the initial treatment of disc displacements involves several conservative measures, among them, the stabilizing interocclusal splint. However, in cases where there is associated opening limitation, such as intermittent lock and closed-lock, arthrocentesis has been suggested as another initial treatment modality due to its faster effect in preventing disease progression to a more advanced stage, in addition to reducing the chances of pain chronicity and central sensitization. Objectives: The present study aimed to compare and analyze the effectiveness and benefits of performing arthrocentesis as the initial treatment in patients with DDWR with intermittent lock and in patients with DDWoR, compared to the stabilizing interocclusal splint. Additionally, it had as secondary objectives to characterize the sample according to demographic, systemic, local and psychosocial factors in both groups and to correlate the clinical characteristics of the included patients with the imaging findings of the MRI scans. Methods: A randomized, prospective, longitudinal pilot study was performed. The sample was obtained by convenience from a demand through consultations and referral, among patients treated at the Oral and Maxillofacial Surgery Service of HCFMUSP, from June 2021 to July 2023. Patients with diagnoses of: DDWR intermittent lock and DDWoR with opening mouth limitation. Study patients underwent an initial assessment using a clinical questionnaire (DC/TMD) and underwent an initial TMJ MRI. Then, they were randomly divided into two groups according to the treatment to which they would be submitted: stabilizing inter-occlusal splint (group 1) or arthrocentesis (group 2). After treatment was instituted, patients were evaluated at 1, 2, 3 and 6 months regarding clinical parameters of pain, functionality and psychosocial status.